Articles by Lyudmila Bazhenova, MD
Taletrectinib is a next-generation targeted therapy for ROS1-positive non-small cell lung cancer that has shown strong and durable tumor responses in both treatment-naïve and previously treated patients. It demonstrates meaningful activity in the brain and maintains a manageable safety profile with mostly mild side effects. Overall, the findings support its use as an effective and well-tolerated treatment option in this patient population.
Lung Cancer Experts Detail Challenges of Cisplatin/Carboplatin Shortages
ByEdward S. Kim, MD, MBA,Heather Wakelee, MD,Karen L. Reckamp, MD, MS,Edgardo S. Santos Castillero, MD, FACP, FASCO,Lyudmila Bazhenova, MD Experts discuss the challenges of the ongoing cisplatin and carboplatin shortages in the United States and detail how they are adapting in their practices.
Lyudmila Bazhenova, MD, professor of clinical medicine, University of California, San Diego, discusses the potential approval of lorlatinib for patients with ALK-positive non–small cell lung cancer (NSCLC).
